Business Context and Reporting Period
This Form 8-K filing by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) covers events occurring between November 29, 2012, and December 10, 2012. The report details the completion of a public offering of common stock and warrants.
Key Financial Metrics
The filing reports gross proceeds from a two-stage equity offering:
- Initial Offering (Completed Dec 4, 2012): Gross proceeds of $6,600,000 from the sale of 19,130,435 Firm Shares and 869,565 Over-allotment Shares, plus associated warrants.
- Remaining Over-allotment (Completed Dec 10, 2012): Gross proceeds of $660,000 from the sale of 2,000,000 Remaining Over-allotment Shares and associated warrants.
- Total Gross Proceeds: $7,260,000 (prior to deducting underwriting discounts, commissions, and offering expenses).
- Offering Price: $0.33 per unit (one share plus a warrant to purchase 0.55 shares).
- Warrant Exercise Price: $0.472 per whole share.
The filing text does not provide clear values for net proceeds, revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in outstanding common stock and warrants resulting from the full exercise of the underwriters' over-allotment option. The company raised an additional $660,000 on December 10, 2012, following the initial closing on December 4, 2012.
Outlook, Risks, and Management Commentary
The filing contains no specific management commentary regarding future guidance, operational outlook, or new risks. The document focuses strictly on the mechanics and completion of the capital raise. No unusual items or contingencies are disclosed beyond the standard terms of the underwriting agreement.
Investor Verification Checklist
- Verify the total number of shares issued (Firm Shares + Over-allotment Shares) to assess dilution impact.
- Confirm the net proceeds after deducting underwriting discounts and offering expenses, as only gross proceeds are listed.
- Review the warrant terms (exercise price of $0.472 and expiration date) to understand potential future dilution.
- Check subsequent filings for the use of proceeds and updated cash position.